Endocrine-Related Cancer

Article	Citations
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	91
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	67
Acknowledgement to reviewers	55
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	54
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	49
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	44
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	44
Targeting growth hormone in cancer: future perspectives	39
Update on the genetics of paragangliomas	36
Acknowledgement to reviewers	36
Celebrating the 80th anniversary of hormone ablation for prostate cancer	36
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients	35
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms	34
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	31
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	30
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	29
Radioiodine treatment: an historical and future perspective	28
Metabolically active brown adipose tissue in PPGL: an observational cohort study	28
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	27
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells	27
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	27
Whole-exome sequencing of rectal neuroendocrine tumors	25
Gender-affirming care and endocrine-related cancers	25
Therapy considerations in neuroendocrine prostate cancer: what next?	24
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	24

Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	23
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	23
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	22
Antitumor immune response is associated with favorable survival in GEP-NEN G3	22
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	21
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	21
Effect of TSH levels during active surveillance of PTMC according to age	20
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	20
Immunotherapy for endocrine tumours: a clinician’s perspective	20
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	20
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer	19
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	19
Steroid profile in patients with breast cancer and in mice treated with mifepristone	19
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	19
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms	18
Exploring stem cell biology in pituitary tumors and derived organoids	18
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis	17
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors	17
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	17
Acknowledgement to reviewers	16
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study	16
Acknowledgement to reviewers	16
From bench to bedside in the sella: translational developments in pituitary tumour genetics	16
Inhibition of GATA2 in prostate cancer by a clinically available small molecule	15
New therapeutic opportunities for women with low-grade serous ovarian cancer	15
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	14
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma	14
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study	14
Efficacy of adavosertib therapy against anaplastic thyroid cancer	14
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	13
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer	13
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	13
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	12
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	12
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus	12
In vivo and in vitro analysis of functional effects of the SDHD H50R variant	12
Genetic disorders and insulinoma/glucagonoma	12
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	12
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	12
Beyond the three P’s: adrenal involvement in MEN1	11
Non-pituitary GH regulation of the tissue microenvironment	11
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	11
Deiodinases in thyroid tumorigenesis	11
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	11
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	11
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	11
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms	11
In memoriam: Charis Eng MD PhD (1962–2024)	10
Sexual dimorphism in thyroid cancer: evidence from preclinical studies	10
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	10

Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis	10
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	10
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	10
Mendelian randomization to investigate the link between TSH and thyroid cancer	10
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	10
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	10
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	9
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	9
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	9
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	9
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	9
Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic revie	9
Surrogate molecular classification of LAR breast cancer in routine workflow	9
Precocious puberty due to intracranial germ cell tumors: a case–control study	9
Management of high-grade neuroendocrine neoplasms: impact of functional imaging	9
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	9
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	9
mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs	9
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors	9
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	9
MicroRNAs as regulators of tumor metabolism	9
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	9
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	9
Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors	9
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	9
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	9
Risk factors for intraoperative complications in pheochromocytomas	8
Adrenal tumors provide insight into the role of cortisol in NK cell activity	8
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer	8
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer	8
Insulinomatosis: new aspects	8
Endocrine cancer trends 1990–2021: global disparities and health inequalities	8
Second-generation hormonotherapy in prostate cancer and bone microenvironment	8
Exploring chromosomal instability and clonal heterogeneity in breast cancer	8
A clinically applicable molecular classification of oncocytic cell thyroid nodules	8
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents	8
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma	8
Inflammation-based score in pediatric adrenocortical carcinoma	7
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix	7
Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature	7
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer	7
A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy	7
Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis	7
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC	7
Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding	7
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	6
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	6
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	6
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer	6
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer	6
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	6
Thyroid status regulates the tumor microenvironment delineating breast cancer fate	6
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	6
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	6
SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination	6
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	6
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing	6
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	6
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	5
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	5
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases	5
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	5
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	5
Progress and challenges in experimental models for pheochromocytoma and paraganglioma	5
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	5
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	5
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	5
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	5
New drug delivery strategies targeting the GnRH receptor in breast and other cancers	5
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	5
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	5
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	5
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation	5
Development and validation of long-acting recombinant human TSH using SAFA technology	4
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma	4
Second primary cancers and survival among neuroendocrine tumor patients	4
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	4
Pregnancy-associated breast cancer: the influence of gestational age	4
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	4
Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study	4

Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma	4
Mechanisms of resistance to RET-directed therapies	4
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	4
Evaluation of modifiable factors and polygenic risk score in thyroid cancer	4
β-Catenin activation and illicit receptor expression in adrenocortical cells	4
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells	4
Therapeutic inhibition of ATR in differentiated thyroid cancer	4
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	4
The role of membrane mucin MUC4 in breast cancer metastasis	4
Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?	4
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?	4
Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer	4
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors	3
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma	3
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	3
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	3
Growth hormone and radiation therapy: friend, foe, or both?	3
Global trends in thyroid cancer 1990–2021: an analysis based on the GBD 2021	3
Aggressive versus indolent insulinomas: new clinicopathological insights	3
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine	3
Mannose enhances anti-tumor effect of PLX4032 in anaplastic thyroid cancer	3
Targeting androgen receptor signaling: a historical perspective	3
Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era	3
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones	3
The role of vitamin D in breast cancer risk and progression	3
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	3
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis	3
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients	3
Autocrine/paracrine growth hormone in cancer progression	3
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review	3
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis	3
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma	3
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers	2
Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy	2
Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome	2
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?	2
A study of acromegaly-associated headache with somatostatin analgesia	2
PARP inhibitors in advanced prostate cancer: when to use them?	2
Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms	2
The tumor microenvironment and immune responses in prostate cancer patients	2
Changes in categorization or nomenclature within neuroendocrine tumors	2
RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis	2
SDHA related phaeochromocytoma and paraganglioma: review and clinical management	2
Urinary androgens excretion patterns and prostate cancer in Mexican men	2
Mechanisms of RET-mediated signal transduction	2
Dysregulation of splicing variants and spliceosome components in breast cancer	2
Immunotherapy-induced isolated ACTH deficiency in cancer therapy	2
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer	2
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns	2
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms	2
RETRACTION: Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress	2
Talking about sex: erectile dysfunction in the oncology patient	2
A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo	2
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline	2
Target therapies plus somatostatin analogs in NETs: a network meta-analysis	2
Body composition in recurrent prostate cancer and the role of steroidogenic genotype	2
TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer	2
The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma	2
Aldosterone-producing nodules and CYP11B1 signaling correlate in primary aldosteronism	2
Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate	2
Key factors for effective mitotane therapy in children with adrenocortical carcinoma	2
Genomic testing for RET in the clinic: UK and global perspective	2
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	2
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome	2
Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis	2
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers	2
Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors	2
PRB inhibited cell proliferation through let-7b-E2F1 in breast cancer	2
Biomarkers for prognosis in pancreatic neuroendocrine tumors	2
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET	2
Disease relapse in relation to lymph node sampling in lung carcinoid patients	2